Results 41 to 50 of about 37,371 (257)

Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases. [PDF]

, 2020
OBJECTIVE: The evolution of non-vitamin K antagonist anticoagulants (NOACs) has changed the horizon of stroke prevention in atrial fibrillation (SPAF).
Acar, RD, Akgün, T, Camm, AJ, Emren, V, Kanat, S, Karacağlar, E, Kepez, A, Kul, Ş, Tülüce, K, Türk, UÖ, Yakar Tülüce, S, Özel, E, Şimşek, E   +12 more
core   +1 more source

Determination of Dabigatran Concentration in Human Plasma and Breast Milk

International Journal of Analytical Chemistry, 2021
Venous thromboembolism (VTE) is an important cause of death following childbirth. Dabigatran etexilate can be a useful prophylaxis in susceptible women during the postpartum period. However, it is not clear whether dabigatran is excreted into breast milk
F. Sidgwick, A. Porter, P. Ayuk, F. Kamali, A. Truemann   +4 more
doaj   +1 more source

Hemopericardium and Cardiac Tamponade Associated with Dabigatran Use [PDF]

, 2012
OBJECTIVE: To describe 2 cases of hemopericardium following treatment with dabigatran. CASE SUMMARIES: A 70-year-old male with a history of dabigatran use presented with cough, fatigue, and bloody stools.
Dy, Eliza A., Shiltz, Dane L.
core   +2 more sources

Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting

Frontiers in Medicine, 2020
Background: Idarucizumab has been included in guidelines for the management of bleeding or surgical procedure in dabigatran-treated patients without need for biological monitoring.
Nicolas Gendron, Nicolas Gendron, Richard Chocron, Richard Chocron, Paul Billoir, Julien Brunier, Laurence Camoin-Jau, Marie Tuffigo, Dorothée Faille, Dorothée Faille, Dorian Teissandier, Juliette Gay, Juliette Gay, Emmanuelle de Raucourt, Emmanuelle de Raucourt, Ludovic Suner, Corentin Bonnet, Anne-Céline Martin, Anne-Céline Martin, Dominique Lasne, Chayma Ladhari, Aurélien Lebreton, Laurent Bertoletti, Laurent Bertoletti, Nadine Ajzenberg, Nadine Ajzenberg, Pascale Gaussem, Pascale Gaussem, Pierre-Emmanuel Morange, Pierre-Emmanuel Morange, Pierre-Emmanuel Morange, Véronique Le Cam Duchez, Alain Viallon, Pierre-Marie Roy, Pierre-Marie Roy, Agnès Lillo-le Louët, Agnès Lillo-le Louët, David M. Smadja, David M. Smadja, David M. Smadja   +39 more
doaj   +1 more source

Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?

Trauma Case Reports, 2021
Dabigatran is an oral anticoagulant directly acting as thrombin inhibitor. The monoclonal antibody idarucizumab was developed to reverse its anticoagulatory effects after application of a standardized dose.
Mathias Ströhle, Christopher Rugg, Stefan Schmid, Dietmar Fries, Elgar Oswald   +4 more
doaj   +1 more source

Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study [PDF]

, 2013
OBJECTIVE: Dabigatran was recently approved for anticoagulation in patients with atrial fibrillation (AF); data regarding real-world use, comparative effectiveness and safety are sparse. DESIGN: Pharmacoepidemiological cohort study.
Charlot, M., Fosbol, E. L., Gislason, G., Hansen, M. L., Hvidtfeldt, M. W., Karasoy, D., Kober, L., Lamberts, M., Lip, G. Y. H., Olesen, J. B., Sorensen, R., Torp-Pedersen, C., Weeke, P.   +12 more
core   +1 more source

Correlation Between Trough Plasma Dabigatran Concentrations and Estimates of Glomerular Filtration Rate Based on Creatinine and Cystatin C [PDF]

, 2014
AIMS: Dabigatran is largely cleared by renal excretion. Renal function is thus a major determinant of trough dabigatran concentrations, which correlate with the risk of thromboembolic and haemorrhagic outcomes.
Berit P. Jensen, Daniel F. B. Wright, David M. Patterson, Evan J. Begg, Mary C. Wallace, Mei Zhang, Murray L. Barclay, Paul K. L. Chin, Rebecca L. Roberts   +8 more
core   +1 more source

DABIGATRAN ETEXILATE FOR PREVENTION OF CARDIOEMBOLIC COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION: HOW TO DO THE INTERVENTION MORE EFFECTIVE AND SAFER

Рациональная фармакотерапия в кардиологии, 2016
Application of dabigatran etexilate for prevention of cardioembolic complications in nonvalvular atrial fibrillation is considered. Results of randomized clinical trials on efficacy and safety of dabigatran in various doses are discussed.
I. S. Yavelov
doaj   +1 more source

Flow Cytometric Assessment of Endothelial and Platelet Microparticles in Patients With Atrial Fibrillation Treated With Dabigatran

Clinical and Applied Thrombosis/Hemostasis, 2020
The prothrombotic state in patients with atrial fibrillation (AF) is related to endothelial injury, the activation of platelets and the coagulation cascade.
Aleksandra Lenart-Migdalska MD, Leszek Drabik MD, PhD, Magdalena Kaźnica-Wiatr MD, PhD, Lidia Tomkiewicz-Pająk MD, PhD, Piotr Podolec MD, PhD, Maria Olszowska MD, PhD   +5 more
doaj   +1 more source

Clinical performance of the atrial fibrillation in the Russian population depending on the antithrombotic therapy: findings from the GLORIA-AF registry phase 2

Российский кардиологический журнал, 2020
Aim. To analyze clinical characteristics of patients with nonvalvular atrial fibrillation (AF) in the Russian population, enrolled in the GLORIA-AF registry phase 2, depending on the antithrombotic therapy received, and to assess the potential for ...
E. V. Shlyakhto, S. V. Villevalde, A. V. Ezhov, S. A. Zenin, N. A. Koziolova, O. Yu. Korennova, T. N. Novikova, K. V. Protasov, G. A. Chumakova, C. Teutsch, S. Lu, G. Y. H. Lip, M. V. Huisman   +12 more
doaj   +1 more source